SCHEMBL10163733

SCHEMBL10163733

Cc1cc(CN2C(=O)c3ccccc3C2=O)nc(Cl)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.54
RECQL P46063 2/20 0.54
ALDH1A1 P00352 6/20 0.49
PKM P14618 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
HPGD P15428 3/20 0.45
GLA P06280 1/20 0.45
GAA P10253 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TYR P14679 3/20 0.44
HTT P42858 3/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
PABPC1 P11940 1/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18506605 0.85 MAPT (0.54) MAPTRECQLALDH1A1PKMMEN1
SCHEMBL29411219 0.85 ALDH1A1 (0.51) MAPTRECQLALDH1A1PKMMEN1
SCHEMBL10163732 0.85 MAPT (0.56) MAPTRECQLALDH1A1PKMMEN1
SCHEMBL3720990 0.85 ALDH1A1 (0.51) MAPTRECQLALDH1A1PKMMEN1
SCHEMBL21854453 0.82 KMT2A (0.49) MAPTRECQLALDH1A1PKMMEN1
SCHEMBL21854476 0.80 ALDH1A1 (0.47) MAPTRECQLALDH1A1PKMMEN1
SCHEMBL18489369 0.79 MAPT (0.54) MAPTRECQLALDH1A1PKMMEN1
SCHEMBL21854415 0.79 ALDH1A1 (0.46) MAPTRECQLALDH1A1PKMMEN1
SCHEMBL21854526 0.78 MAPT (0.43) MAPTRECQLALDH1A1PKMMEN1
SCHEMBL18489387 0.77 CASP3 (0.50) MAPTRECQLALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120083474-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083474-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 TRPA1, TRPV1, TRPV2 MAPT 1004/4885RECQL 2092/4885ALDH1A1 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.